Evidence map›Paper›PMID 32899210›Full record

ArticleCancers2020

Drug Vulnerabilities and Disease Prognosis Linked to the Stem Cell-Like Gene Expression Program Triggered by the RHO GTPase Activator VAV2 in Hyperplastic Keratinocytes and Head and Neck Cancer.

Luis Francisco Lorenzo-Martín, Mauricio Menacho-Márquez, Xosé R Bustelo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Luis Francisco Lorenzo-MartínCentro de Investigación del Cáncer, CSIC-University of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0003-4717-9338
Mauricio Menacho-MárquezCentro de Investigación del Cáncer, CSIC-University of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0003-3628-8627
Xosé R BusteloCentro de Investigación del Cáncer, CSIC-University of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0001-9398-6072
Universidad de Salamanca · ES

Funding

Consejería de Educación, Junta de Castilla y León CLC-2017-01Consejería de Educación, Junta de Castilla y León CSI049U16Fundación Científica Asociación Española Contra el Cáncer GC16173472GARCMinisterio de Ciencia, Innovación y Universidades RTI2018-096481-B-I00Ministerio de Educación, Cultura y Deporte FPU13/02923Worldwide Cancer Research 14-1248
6 · The paper itself

Abstract

We have recently shown that VAV2, a guanosine nucleotide exchange factor that catalyzes the stimulation step of RHO GTPases, is involved in a stem cell-like (SCL) regenerative proliferation program that is important for the development and subsequent maintenance of the tumorigenesis of both cutaneous (cSCC) and head and neck squamous cell carcinomas (hnSCC). In line with this, we have observed that the levels of the

Indexed as

cancerGTPaseshead and neckkeratinocytesoncogenesRac1regenerative proliferationRhoAsignalingskinstem cellsVAV2VAV family

Identifiers

PMID32899210
PMCPMC7563609
OpenAlexW3081611436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.